anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A system for reading RFID tags of articles within a cabinet includes a repositionable shelf. The repositionable shelf includes an antenna assembly having three antenna pairs. Each antenna pair has a loop antenna and a figure eight antenna. The antenna pairs are on a PC board. The PC board includes an RJ45 connector which provides both power to the antenna assembly as well as a communication interface for the antenna assembly. The RJ45 connector could be used to provide the RF signals from the antenna to a reader. The system could also include a repositionable divider for placement perpendicular to the repositionable shelf. The repositionable divider also includes a loop antenna and a figure eight antenna.
This is a phase 2 intention-to-treat study of salvage chemotherapy followed by allogeneic HSC transplant for the treatment of primary refractory or relapsed HL. Patients who 1) do not progress on salvage chemotherapy, and 2) have both suitable HSC donors and 3) a satisfactory pre-allograft work-up will proceed to allograft. Patients who fail any of these 3 criteria will be off-study and considered treatment failures for the purposes of the intention-to-treat study.
Each patient and his partner will fill out assessments at baseline. Thereafter we will obtain the patients' treatment decision (AT or AS) within approximately 6 months. Once a patient makes a decision, he and his partner will complete another set of questionnaires. The patient and his partner will then complete the remaining questionnaires approximately 6, 12, 18, and 24 months following the treatment decision. We will examine the associations between baseline assessments , and the treatment decision as well as the changes in the assessments and the treatment decision. We will also assess associations between follow-up assessments and the decision to change a treatment decision from AS to AT. Data from patients and partners/close allies will generally be analyzed separately, thus patients who do not have a partner (or partner declines to participate) can still be enrolled and their psychosocial outcomes assessed.
Verapamil hydrochloride extended-release tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug.

Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).

Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly.

Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal.

Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy.
Twice daily oral atovaquone will be added to standard concurrent chemoradiotherapy (CRT): 66 Gy in 33 fractions, once daily, 5 days a week (Monday-Friday), with cisplatin (80 mg/m2 IV on days 1 and 22 of CRT) and vinorelbine (15 mg/m2 IV on days 1, 8, 22 and 29 of CRT). Whilst awaiting CRT to start, patients will receive two weeks (+/- 7 days) of oral atovaquone to ensure steady state is reached (after seven days). Patients will be allocated one of four dose levels: 450 mg, 600 mg, 675 mg or 750 mg (all doses PO BD). Atovaquone dose will be assigned as per the TiTE-CRM statistical model. The first two trial participants will receive 450 mg BD. In the absence of unacceptable toxicity, subsequent patients will be assigned doses up to and including 750 mg BD.

Hypoxia biomarker data will be collected at baseline (start of atovaquone run-in) and following two weeks (+/- 7 days) of atovaquone treatment. Atovaquone will then be continued without break for the duration of CRT, with the CRT schedule remaining constant for all patients at both centres. Assessment for Dose Limiting Toxicities (DLTs) will be from the first scheduled dose of atovaquone until three months after completion of CRT. The CT scan performed at the three-month follow up visit will be reviewed to collect tumour response data.
Participants in Part 1 received 70mg alendronate tablet in Period 1 followed by 70mg alendronate+5600 IU vitamin D combination tablet in Period 2. A washout of at least 12 days separated each treatment period.
PROBLEM TO BE SOLVED: To provide the subject coated sheet, causing no problem when adhering to the skin, e.g. stimulating or roughening the skin, and capable of efficiently supplying a given agent to, and allowing it to act on, the target portion by including a polyolefin-based resin and agent which acts on the skin or hair. SOLUTION: This coated sheet is obtained by including (A) 100 pts.wt. of a polyolefin-based resin and (B) 0.01 to 100 pts.wt. of an agent which acts on the skin or hair. The preferable component A is an α-olefin polymer (e.g. polyethylene), which may be incorporated with a thermoplastic elastomer preferably at 20 to 60 pts.wt. per 100 pts.wt. of the component A. The examples of the component B include a humectant, skin-whitening agent and ultraviolet ray absorbent, preferably oily (e.g. tallow, butyric acid, lauryl alcohol, liquid paraffin and carnauba wax). The coated sheet preferably has an adhesion of at least 5,000 cN/cm<2> , when adhered to each other.
Participants first receive placebo at their first session in the laboratory. Then will return to the laboratory 72 hours later and will receive 20 mg methamphetamine.
The invention relates to a composition of creatine phosphate and arginine. The composition contains creatine phosphate and arginine that are in an optimal weight ratio of 1:1.65 (calculated on a dry and pure basis according to a drug content determination method). The composition can dissolve acidic creatine phosphate with poor solubility and adjust the pH value to neutrality that is suitable for injection, and the obtained solution is clear and transparent. The composition has good solubility and fluidity, and can be subpackaged into practical powder injection preparations for injection. More crucially, the stability of the composition has unexpected improvements that: 1. the composition has good stability to high temperature, can be stored at room temperature, while the currently used creatine phosphate sodium is sensitive to temperature, so the thermal stability of the composition is obviously improved; and 2. when the composition is added into a 5% glucose or (and) 0.9% chloride sodium large volume infusion solution for use, the stability of the composition solution is obviously higher than that of the currently used creatine phosphate sodium. Therefore, the composition provided in the invention has substantially improved stability than currently used creatine phosphate sodium, and is more convenient to store and safer to use, thus having practical significance.
PURPOSE: Circular RNAs (circRNAs) are increasingly recognized for their important roles in various cancers, including papillary thyroid cancer (PTC). The specific mechanisms by which the circLIF receptor subunit alpha (circLIFR, hsa_circ_0072309) influences PTC progression remain largely unknown.
METHODS: In our study, CircLIFR, miR-429, and TIMP2 levels were assessed using reverse transcription-quantitative PCR. The roles of circLIFR and miR-429 in PTC cells were determined using Cell Counting Kit-8, colony formation, wound healing, and Transwell assays. Western blotting was utilized to examine the levels of TIMP2. The direct interaction between circLIFR, TIMP2, and miR-429 was confirmed using dual-luciferase reporter, RNA immunoprecipitation, and fluorescence in situ hybridization assays.
RESULTS: In PTC tissues and cells, a decrease in circLIFR and TIMP2 levels, accompanied by an increase in miR-429 levels, was observed. Overexpression of circLIFR or downregulation of miR-429 effectively suppressed the proliferation and migration of PTC cells. Conversely, the knockdown of circLIFR or overexpression of miR-429 had the opposite effect. Furthermore, circLIFR overexpression suppressed tumor growth in vivo. Mechanistically, circLIFR modulated TIMP2 expression by serving as a sponge for miR-429. Rescue experiments indicated that the antitumor effect of circLIFR could be reversed by miR-429.
CONCLUSION: This study confirmed circLIFR as a novel tumor suppressor delayed PTC progression through the miR-429/TIMP2 axis. These findings suggested that circLIFR held promise as a potential therapeutic target for PTC.
The Mood Disorder Cohort Research Consortium (MDCRC) study is designed as a naturalistic observational prospective cohort study for early-onset mood disorders (major depressive disorders, bipolar disorders type 1 and 2) in South Korea. The study subjects consist of two populations: 1) patients with mood disorders under 25 years old and 2) patients with mood disorders within 2 years of treatment under 35 years old. After successful screening, the subjects are evaluated using baseline assessments and serial follow-up assessments at 3-month intervals. Between the follow-up assessments, subjects are dictated to check their own daily mood status before bedtime using the eMood chart application or a paper mood diary. In addition, wearable activity tracker(Fitbit charge series) is applied for data collection such as activity, sleep, and heart rate during every moments. At the regular visits every 3 months, inter-visit assessments are evaluated based on daily mood charts and interviews with patients. In addition to the daily mood chart, sleep quality, inter-visit major and minor mood episodes, stressful life events, and medical usage pattern with medical expenses are also assessed. Genomic DNA from blood is obtained for genomic analyses. From the MDCRC study, the clinical course, prognosis, and related factors of early-onset mood disorders can be clarified. The MDCRC is also able to facilitate translational research for mood disorders and provide a resource for the convergence study of mood disorders.
Participants in this arm will receive a talking intervention designed to explore their interest in reducing/eliminating alcohol use. Sessions will occur at the baseline interview and every three months for 18 months.
Transient tinnitus occurred in eight tobramycin inhalation solution treated patients versus no placebo patients in the clinical studies. Tinnitus may be a sentinel symptom of ototoxicity, and therefore the onset of this symptom warrants further clinical investigation. In postmarketing experience, patients receiving tobramycin inhalation solution have reported hearing loss. Ototoxicity, manifested as both auditory and vestibular toxicity, has been reported with parenteral aminoglycosides. Vestibular toxicity may be manifested by vertigo, ataxia or dizziness. Patients with known or suspected auditory or vestibular dysfunction should be closely monitored when taking tobramycin inhalation solution. Monitoring might include obtaining audiometric evaluations and serum tobramycin levels. If ototoxicity is noted, the patient should be managed as medically appropriate, including potentially discontinuing tobramycin inhalation solution [see Adverse Reactions (6.2)].
Within each of the 5 single dose treatment periods, 6 participants with mild to moderate hypertension received a single dose of MK-8892 0.5 mg, 1.0 mg, 2.0 mg or 6.0 mg, and 2 participants received placebo. Dosages will be determined by the results of Panels A and B.
This study will be a Randomized Controlled Trail conducted at Horizon hospital, Lahore. The study will be completed within the time duration of Six months. Consecutive sampling technique will be used to collect the data. The sample size of 44 patients will be taken in this study to find the effects of ESWT on pain, ROM, functional mobility. Patient will be divided into two groups. Group A will be treated with ESWT with conventional therapy and Group B will be treated with conventional therapy. Constant Shoulder Score (CSS) and the Oxford Shoulder Score (OSS) tools will be used to measure the outcomes of the study.

One session of treatment per week for four weeks will be given. Pretest, posttest at 4th week and followup of 24th weeks will be evaluated.
Nicotinoyl benzoguanamine derivatives of formula (I) and their acid addn. salts are prepd. by reacting benzoguanamine derivatives (II) with activated nicotinic acid derivatives. In the formula (I), X,Y (same or different) are H, halogen (X=Y=H excluded), Z=mono or di lower alkyl amino, piperidino, pyrrolidino or morpholino. The novel compds. are reversed passive Arthus rxn. (RPAR) inhibitors.  The RPAR inhibitor is useful for treating rheumatism and allergic nephritis.
Prior to reconstitution, the dual-chamber NATPARA medication cartridge should be stored in the package provided at refrigerated temperature, 36 to 46°F (2 to 8°C). After reconstitution, the medication cartridge should be stored in the Q-Cliq pen under refrigeration at 36 to 46°F (2 to 8°C). The reconstituted product can be used for up to 14 days under these conditions. Store away from heat and light. Avoid exposure to elevated temperatures. Discard reconstituted NATPARA medication cartridges after 14 days.

Do not freeze or shake. Do not use NATPARA if it has been frozen or shaken.

The mixing device and empty Q-Cliq pen can be stored at room temperature.

Safely discard needles.
The invention provides a method of acoustic antenna beam steering without the physical movement of the antenna itself using an acoustic is cell the transmission characteristics of which can be modified by an applied electric field. The invention proposes the construction and use of such a cell using an Electro-Rheological (ER) fluid. The essence of the cell is a film of ER fluid 12 through which the sound is to be passed. It is arranged that an electrical voltage 14 can be applied across the fluid film. As this voltage is varied the transmission of sound through the ER fluid is modified such that, for a constant source of sound impinging upon the cell, the characteristics of the output sound wave 16 are altered - specifically, in both phase and amplitude - compared with the input wave 15. <IMAGE>
Healthy control subjects will be matched by age, gender, education, ect. to cerebral metastases subjects. Each will have fMRI scannings (3 total), neuropsychological testings (3 total), and quality of life assessments (3 total) at the same time points as their matched cerebral metastases subject.
The first type, called "A" Cohorts, corresponds to indications for which the treatment induces a high response rate (\>30%). These patients will have a lymphapheresis before and during treatment with immunotherapy. In addition, a blood sample in CellSave® tubes (15mL) will be taken at baseline and three weeks, and EDTA tubes (15mL) will be taken at baseline, 3 weeks after treatment start and at progression.
The invention comprises salts of elenolic acid of general formula (C11H13O6)nM, where M i sodium, potassium, ammonium, calcium, magnesium, zinc or ferrous iron and n is the valency of M; ethers of elenolic acid and its esters of general formula C11H13O6R and C11H12O6(R)2 respectively, where R is an alkyl group of less than six carbon atoms; and a process for the preparation of elenolic acid concentrates by extracting parts of plants of the Oleaceae family with a water-immiscible organic solvent, separating the neutral constituents from the extract by evaporation to dryness, solution of the residue in an aqueous bicarbonate solution of pH 7-7.5, and solvent extraction, whereafter the elenolic acid portion is isolated by acidification of the aqueous phase and extraction with a water-immiscible solvent, e.g. chloroform or ether.  Detailed examples illustrate the extraction of elenolic acid from Olea europea and the preparation of its salts, elenolide, and the methyl and ethyl ethers of elenolic acid and its methyl and ethyl esters.ALSO:Concentrates of elenolic acid, C11H14O6 are prepared by extracting parts of plants of the Oleaceae family with a non-water miscible organic solvent, removing the neutral constituents from the extract by evaporating it to dryness, treating an aqueous solution of the residue with bicarbonate (to pH 7-7.5) adding a water-soluble salt, and extracting with a non-water miscible organic solvent, then acidifying the aqueous phase and extracting the elenolic acid with a non-water miscible organic solvent, e.g. chloroform or ether. Elenolic acid, its salts, e.g. magnesium, calcium, zinc, ferrous, ammonium sodium and potassium, elenolide, and acetals and acetalesters of elenolic acid are hypotensive agents which may be administered orally, as suspensions or solutions but preferably in solid form coated against the action of gastric acid, parenterally as an aqueous solution suitable for injection, or by incorporation in suppositories.
Stage 1 (Phase II Study) For 80% power (β = 0.20), at a significance level of 5% (α =0.05) and a 1:1 randomization ratio, a total of 316 (EB05: 158, SOC: 158) evaluable patients will be required. Allowing for 20% attrition a total of 396 patients will be recruited.
A final three-week wash-out period. All participants will attend 6 measurement sessions across the 3-week period but will not complete either the standard of care or the experimental swallowing exercises.
The invention discloses a tumor-targeted polymer micelle, comprising a first polymer carrier modified with a targeting ligand, Lancovutide, and affinitive to a cell membrane component, phosphatidyl ethanolamine. The first polymer carrier is a copolymer of polyethylene glycol and DL-polylactide. The micelle further comprises a second polymer carrier for covering the first polymer carrier to form a core-shell mixed micelle; the second polymer carrier is unstable in an acidic environment of tumor tissues and depolymerizes at a pH value: 6.0-6.5. The second polymer carrier is a copolymer of polyethylene glycol and poly-L-histidine. On the basis of the cell membrane component, phosphatidyl ethanolamine, being external in M-phase cell mitosis and of the tumor tissues being acidic, the function of a cell cycle specific targeting carrier is achieved, and this carrier is high in efficiency, low in toxicity and suitable for targeted therapy of tumor cells. The invention further discloses a preparation method of the tumor-targeted polymer micelle.
BACKGROUND: Peripheral artery disease (PAD) is an ischemic disease with a rising incidence worldwide. The lncRNA H19 (H19) is enriched in endothelial progenitor cells (EPCs), and transplantation of pyroptosis-resistant H19-overexpressed EPCs (oe-H19-EPCs) may promote vasculogenesis and blood flow recovery in PAD, especially with critical limb ischemia (CLI).
METHODS: EPCs isolated from human peripheral blood was characterized using immunofluorescence and flow cytometry. Cell proliferation was determined with CCK8 and EdU assays. Cell migration was assessed by Transwell and wound healing assays. The angiogenic potential was evaluated using tube formation assay. The pyroptosis pathway-related protein in EPCs was detected by western blot. The binding sites of H19 and FADD on miR-107 were analyzed using Luciferase assays. In vivo, oe-H19-EPCs were transplanted into a mouse ischemic limb model, and blood flow was detected by laser Doppler imaging. The transcriptional landscape behind the therapeutic effects of oe-H19-EPCs on ischemic limbs were examined with whole transcriptome sequencing.
RESULTS: Overexpression of H19 in EPCs led to an increase in proliferation, migration, and tube formation abilities. These effects were mediated through pyroptosis pathway, which is regulated by the H19/miR-107/FADD axis. Transplantation of oe-H19-EPCs in a mouse ischemic limb model promoted vasculogenesis and blood flow recovery. Whole transcriptome sequencing indicated significant activation of vasculogenesis pathway in the ischemic limbs following treatment with oe-H19-EPCs.
CONCLUSIONS: Overexpression of H19 increases FADD level by competitively binding to miR-107, leading to enhanced proliferation, migration, vasculogenesis, and inhibition of pyroptosis in EPCs. These effects ultimately promote the recovery of blood flow in CLI.